ANI Pharmaceuticals Acquires Inderal XL and InnoPran XL

ANI Pharmaceuticals, Inc. announced that it has acquired Inderal XL from Cranford Pharmaceuticals, LLC and InnoPran XL  from Holmdel Pharmaceuticals LP. The acquired assets include the NDA and trademark for InnoPran XL including a license to an Orange Book listed patent, and a distribution license and trademark for Inderal XL as well as finished goods inventory of both products.  Inderal XL and InnoPran XL are currently available in 80mg and 120mg sustained release capsules and are indicated for hypertension.  Inderal XL and InnoPran XL generated combined sales of $23.3 million in calendar year 2016, according to IMS Health.  The acquisitions were funded through a combination of cash and debt.

In conjunction with today’s announcement, ANI has immediately begun selling both Inderal XL 80mg and 120mg sustained release capsules as well as InnoPran XL 80mg and 120mg sustained release capsules under their current labels.  ANI will transition both products to the ANI label at a future date.

Arthur S. Przybyl, ANI’s President and CEO stated, “We are excited to add these two patent protected products to our existing brand business and to further extend our commercial portfolio of brand and generic extended release beta blockers.”